Immix Biopharma, Inc. Cash Flow Statement
IMMX|3 years of annual SEC 10-K data (FY2023-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
Immix Biopharma, Inc. used $15M in operating cash flow and negative free cash flow of $16M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.83 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Net Income | -$21.6M | -$15.4M | -$8.2M |
| Depreciation & Amortization | $32.9K | $5.5K | $2.1K |
| Operating Cash Flow | -$14.6M | -$11.4M | -$7.4M |
| Capital Expenditures | $1.2M | $52.1K | $52.1K |
| Free Cash Flow | -$15.8M | -$11.4M | -$7.5M |
| Share Buybacks | - | - | $100.0K |
| FCF Margin | -78.9% | -57.1% | -37.3% |